Today, the European Union Drugs Agency (EUDA) officially starts work in Lisbon replacing the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The development is the result of legislation entering into application today, which revises the EMCDDA mandate and name and formally establishes the EUDA. With new tools and competencies, the EUDA will play a key role in strengthening the EU’s response to emerging health and security challenges posed by illicit drugs.
Why a new agency?
Following an external evaluation of the EMCDDA, the European Commission called for a broader and more proactive remit for the agency in January 2022 to help it address new challenges posed by an increasingly complex drug phenomenon and the emergence of potent new substances. The EU legislative process was concluded in June 2023, setting the EMCDDA on a one-year transition course to becoming the EUDA.
New services
The ultimate goal of the EUDA is to strengthen the European Union’s preparedness on drugs. Its work will be organised around four inter-connected service categories:
- Anticipate: Helping the EU and its Member States anticipate future drug-related challenges and their consequences.
- Alert: Issuing real-time alerts on new drug risks and threats to health and security.
- Respond: Helping the EU and its Member States strengthen their responses to the drug phenomenon.
- Learn: Facilitating EU-wide knowledge exchange and learning for evidence-based drug policies and interventions.
New mechanisms
To ensure EU preparedness in the drugs field, new mechanisms have been created, including:
- European Drug Alert System, which will issue alerts when serious drug-related risks appear on the market. This complements the existing EU Early Warning System (EWS) on new psychoactive substances.
- European Threat Assessment System, which will boost how the EU prepares for, and reacts to, emerging or potential health and security threats.
- European Network of Forensic and Toxicological Laboratories, which will foster information exchange on new trends and train national toxicologists and forensic drug experts.
From 4–5 July, the EUDA will host its inaugural Management Board meeting, chaired by Dr Franz Pietsch (Austria). This closed event will bring together for the first time the formally nominated Board members to take key institutional decisions linked to the new EUDA regulation. The representative for Bulgaria is the director of the Directorate “Mental Health and Prevention of Addictions” at the National Center of Public Health and Analyses, Dr. Zahari Zarkov.
The Board will adopt its rules of procedure and elect members to the Executive Board and Budget Committee. It will also appoint members to the EUDA Scientific Committee and approve a list of experts for risk assessments of new psychoactive substances. A list of EUDA national focal points (and their heads) and of national representative laboratories appointed to the EUDA network of forensic and toxicological laboratories will also be presented to the Board. The unit that will continue to perform the function of a National Focal Point on Drugs and Drug Addictions for Bulgaria at EUDA will be the “National Focal Point” department at the National Center of Public Health and Analyses.
Source: News Release, EUDA